United States Bacterial Pharyngitis Drugs Market 2025 | Growth Drivers, Trends & Market Forecast, Competitive Landscape & Investment Opportunities

Market Size and growth

The global bacterial pharyngitis drugs market reached US$ 2.5 billion in 2023 and is expected to reach US$ 3.6 billion by 2031, growing with a CAGR of 4.8% during the forecast period 2024-2031.

Key Development:

United States: Recent Industry Developments

✅ In September 2025, AstraZeneca launched a direct-to-consumer platform to expand access to medications for U.S. patients, including those living with chronic conditions. This initiative aims to offer greater convenience and accessibility to patients in need of treatments.

✅ In March 2025, the FDA approved GSK's antibiotic Blujepa (gepotidacin) for treating uncomplicated urinary tract infections in women and girls aged 12 and older. This approval is part of GSK's strategy to counter revenue losses from their leading medicines and upcoming patent expirations on HIV treatments.

Japan: Recent Industry Developments

✅ In September 2025, Kyowa Kirin announced top-line results from the Phase 3 ASCEND long-term extension study of rocatinlimab in adults with moderate-to-severe atopic dermatitis. The company continues to invest in drug discovery and biotechnology innovation to deliver novel medicines with life-changing value.

✅ In August 2025, Shionogi & Co., Ltd. announced plans to build a new manufacturing plant in the U.S. to produce Cefiderocol (Fetroja), a drug for treating Gram-negative bacterial infections. This move is in response to increasing demand and potential tariffs on pharmaceuticals.

✅ In August 2025, Japan's Ministry of Health, Labour and Welfare invested an additional USD 1 million to support GARDP's activities from April 2025 to March 2026, bringing the total investment to USD 10 million since 2020. This funding supports GARDP's discovery and exploratory research to identify new antibiotic candidates and develop new treatments for serious bacterial infections.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/bacterial-pharyngitis-drugs-market?sb

Recent Mergers and Acquisitions

United States: Recent M&A Developments

✅ In May 2025, Paratek Pharmaceuticals completed its acquisition of Optinose, Inc., expanding its portfolio to include XHANCE® (fluticasone propionate), a nasal steroid spray for chronic rhinosinusitis. This acquisition broadens Paratek's commercial portfolio, which now includes both its flagship antibiotic, NUZYRA® (omadacycline), and Optinose's product XHANCE®.

✅ In March 2025, Sunshine Biopharma expanded its presence in the global antibiotics market by acquiring the marketing rights for two new antibiotics in Canada. This strategic move aims to enhance Sunshine Biopharma's portfolio and market reach in the treatment of bacterial infections.

Key Players:

=> Novartis AG, Aurobindo Pharma, AdvoCare Pharma, Pfizer, Cipla Inc., Aden Healthcare, Teva Pharmaceutical Industries Ltd., Orchid Pharma, Lupin, and Medopharm.

Growth Forecast Projected:

The Global bacterial pharyngitis drugs Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global bacterial pharyngitis drugs Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=bacterial-pharyngitis-drugs-market

Key Segments:

➥ By Infection Type: Acute, Chronic

➥ By Bacteria Type: Group A Streptococcus, Group B Streptococcus, Group C Streptococcus, Group D Streptococcus, Group G Streptococcus

➥ By Drug Class: NSAIDs, Anti-Histamines, Others

➥ By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

Regional Analysis for bacterial pharyngitis drugs Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among bacterial pharyngitis drugs producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze bacterial pharyngitis drugs revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/bacterial-pharyngitis-drugs-market?sb

FAQ

What is the current size of the bacterial pharyngitis drugs Market?

A: In 2023, the bacterial pharyngitis drugs Market was valued at US$ 2.5 billion, reflecting its strong industry presence.

Q2: How large is the bacterial pharyngitis drugs Market expected to be by 2031?

A: By 2031, industry forecasts suggest the bacterial pharyngitis drugs Market will grow to around US$ 3.6 billion , demonstrating significant expansion.

Q3: What is the growth rate of the bacterial pharyngitis drugs Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 4.8% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us
-

Company
Name: DataM Intelligence

Contact Person: Sai Kiran

Email: Sai.k@datamintelligence.com

Phone: +1 877 441 4866

Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.